ABSTRACT Objetives: The incidence of posttransplant diabetes and the elevated cardiovascular (CV) risk among transplant recipients are on the rise. Glucagon-like peptide agonists have the potential to mitigate the effects of immunosuppressive drugs, addressing both hyperglycemia and weight gain. This makes them appealing for use in this population, given their CV and renoprotective benefits. Nevertheless, there is insufficient substantial evidence regarding their efficacy in diabetic kidney transplant recipients (KTR). Methods: The objective of this retrospective study was to assess the effectiveness and safety of glucagon-like peptide agonists in KTR. The primary focus was to evaluate their impact on various parameters, such as hemoglobin A1c levels, body mass index (BMI), lipid panel, hemoglobin levels, renal allograft function (estimated glomerular filtration rate [eGFR]), and urinary protein-to-creatinine ratio. Results: During a median observation period of 18 months, this investigation included 64 renal transplant patients. Median eGFR at baseline was 61.9 mL/min/1.73 m2 and remained stable throughout the follow-up. Median HbA1cdecreased from 7.5 to 7% (95%CI; p < 0.002). A significant improvement in BMI and lipid panel were also observed. We did not observed significant changes regarding median creatinine and urinary protein:creatinine ratio levels. No side effects justified discontinuation of the drug. Conclusion: This study shows that the use of glucagon-like peptide agonists is feasible and well-tolerated in KTR, with no significant side effects observed. Subsequent studies are needed to explore whether glucagon-like peptide agonists can effectively improve allograft survival in these patients. Objetives (CV rise Glucagonlike Glucagon like drugs gain population benefits Nevertheless KTR . (KTR) Methods glucagonlike glucagon parameters Ac c levels BMI, , (BMI) estimated eGFR, [eGFR]) proteintocreatinine protein Results 1 months 6 patients 619 61 9 61. mLmin173 mLmin mL min 73 mL/min/1.7 m followup. followup follow up. up follow-up HbAcdecreased HbA cdecreased 75 7 5 7. 95%CI 95CI CI 95 (95%CI 0.002. 0002 0.002 0 002 0.002) proteincreatinine drug Conclusion welltolerated well tolerated (KTR (BMI [eGFR] mLmin17 mL/min/1. 000 0.00 00 [eGFR mLmin1 mL/min/1 0.0 mL/min/ 0. mL/min

RESUMO Objetivos: A incidência de diabetes pós-transplante e o aumento do risco cardiovascular entre os receptores de transplante estão em ascensão. Os agonistas do receptor de peptídeo semelhante ao glucagon têm o potencial de mitigar os efeitos dos medicamentos imunossupressores, abordando tanto a hiperglicemia quanto o aumento de peso, o que os torna atrativos para uso nesta população, dadas as suas vantagens cardiovasculares e renoprotetoras. No entanto, a evidência atual é insuficiente sobre a sua eficácia em receptores de transplante renal diabéticos (RTRD). Métodos: O objetivo deste estudo retrospectivo foi avaliar a eficácia e segurança dos agonistas do peptídeo semelhante ao glucagon-1 em RTRD. O foco principal foi avaliar o seu impacto em vários parâmetros, tais como níveis de hemoglobina A1c, índice de massa corporal (IMC), perfil lipídico, níveis de hemoglobina, função do enxerto renal (taxa de filtração glomerular estimada [TFGe]) e relação proteína-creatinina urinária. Resultados: Durante um período de observação mediano de 18 meses, esta investigação incluiu 64 pacientes transplantados renais. A TFGe mediana no início foi de 61,9 mL/min/1,73 m2 e permaneceu estável durante o acompanhamento. A mediana da HbA1c diminuiu de 7,5 para 7% (IC95%; p < 0,002). Também foi observada uma melhoria significativa no IMC e no perfil lipídico. Não foram observadas mudanças significativas nos níveis medianos de creatinina e relação proteína:creatinina urinária. Nenhum efeito colateral justificou a descontinuação do medicamento. Conclusão: Este estudo mostra que o uso de agonistas do peptídeo semelhante ao glucagon é viável e bem tolerado em RTRD, sem efeitos colaterais significativos observados. Estudos subsequentes são necessários para explorar se esta terapêutica pode melhorar efetivamente a sobrevida do aloenxerto nesses pacientes. Objetivos póstransplante pós ascensão imunossupressores peso população renoprotetoras entanto RTRD . (RTRD) Métodos glucagon1 1 glucagon- parâmetros A1c Ac c IMC, , (IMC) lipídico taxa [TFGe] proteínacreatinina proteína urinária Resultados meses 6 renais 619 61 9 61, mLmin173 mLmin mL min 73 mL/min/1,7 m acompanhamento HbAc HbA 75 7 5 7, IC95% IC95 IC (IC95% 0,002. 0002 0,002 0 002 0,002) medicamento Conclusão observados (RTRD (IMC [TFGe mLmin17 mL/min/1, IC9 (IC95 000 0,00 00 mLmin1 mL/min/1 (IC9 0,0 mL/min/ (IC 0, mL/min

ABSTRACT Introduction: Considering the rising occurrence of posttranplant diabetes and the elevated cardiovascular burden among transplant recipients, the utilization of SGLT2 inhibitors (SGLT2i) in this group is appealing because of their cardiovascular and renoprotective benefits. Nevertheless, there is a scarcity of evidence for diabetic kidney transplant recipients (DKTRs) owing to concerns about potential renal graft damage and adverse effects. Methods: This retrospective study was devised to assess the effectiveness and safety of SGLT2i in kidney transplant recipients (KTRs). The main focus was on evaluating their impact on parameters such as haemoglobin A1c levels, body mass index (BMI), lipid panel, haemoglobin levels, renal allograft function (estimated glomerular filtration rate) and urirnary protein-to-creatinine ratio. Results: A total of 75 renal transplant patients were included in this investigation. The study spanned a median observation period of 18 (2.0–71.0) months. Median estimated glomerular filtration rate at baseline was 61,9 (26–120) mL/min/1.73 m2 and remained stable throughout the follow-up. Median HbA1cdecreased from 7.5 to 7.0% (95% CI; p<0,002). A significant improvement in BMI (95% CI; p<0,001) and lipid panel (95% CI; p<0,05) were also observed. Median haemoglobin rate at baseline was 13,5g/dL and modestly improved at end of follow-up to 13,7g/dL (p=0,12). Regarding urinary protein:creatinine ratio, levels slightly but not significantly rose [+0.05 g/g (p=0,9)]. In a post-hoc subgroup analysis, the rate of urinary tract infections was low (10%). No other side effects were observed during the treatment course. Conclusions: This study demonstrates that the administration of SGLT2i is viable and well-tolerated, with no notable side effects observed in KTRs. However, the question of whether SGLT2i can effectively lower cardiovascular mortality and enhance allograft survival in these patients remains to be explored in subsequent studies. Introduction SGLT SGLTi i (SGLT2i benefits Nevertheless DKTRs (DKTRs Methods KTRs . (KTRs) Ac c BMI, , (BMI) proteintocreatinine protein creatinine ratio Results 7 investigation 1 2.0–71.0 20710 2 0 71 (2.0–71.0 months 619 61 9 61, 26–120 26120 26 120 (26–120 mLmin173 mLmin mL min 73 mL/min/1.7 m followup. followup follow up. up HbAcdecreased HbA cdecreased 5 7. 70 7.0 95% 95 (95 CI p<0,002. p0002 p p<0,002 002 p<0,002) p<0,001 p0001 001 p<0,05 p005 05 135gdL gdL 13 5g dL g 137gdL 7g p=0,12. p012 p=0,12 12 (p=0,12) proteincreatinine +0.05 005 [+0.0 gg p=0,9. p09 p=0,9 (p=0,9)] posthoc post hoc analysis 10%. 10 10% (10%) course Conclusions welltolerated, welltolerated well tolerated, tolerated well-tolerated However studies (KTRs (BMI 2.0–71. 2071 (2.0–71. 6 26–12 2612 (26–12 mLmin17 mL/min/1. (9 p000 p<0,00 00 p<0,0 p00 p01 p=0,1 (p=0,12 +0.0 [+0. p0 p=0, (p=0,9) (10% 2.0–71 207 (2.0–71 26–1 261 (26–1 mLmin1 mL/min/1 ( p<0, (p=0,1 +0. [+0 p=0 (p=0,9 (10 2.0–7 20 (2.0–7 26– (26– mL/min/ p<0 (p=0, +0 [+ p= (1 2.0– (2.0– (26 mL/min p< (p=0 + [ 2.0 (2.0 (2 (p= 2. (2. (p

RESUMO Introdução: Considerando o aumento da incidência de diabetes pós-transplante e o elevado impacto cardiovascular entre os receptores de transplantes, este facto faz com que o uso de inibidores de SGLT2 nesse grupo seja atrativo devido aos seus benefícios cardiovasculares e renoprotetores. No entanto, há escassez de evidência nos receptores de transplante renal com diabetes devido a preocupações com possíveis danos ao enxerto renal e efeitos adversos. Métodos: Este estudo retrospectivo foi elaborado para avaliar a eficácia e segurança dos inibidores de SGLT2 em receptores de transplante renal (KTRs). O foco principal foi avaliar o seu impacto em parâmetros como níveis de hemoglobina A1c, índice de massa corporal (IMC), perfil lipídico, níveis de hemoglobina, função do enxerto renal (taxa de filtração glomerular estimada) e relação proteína/creatinina urinária. Resultados: Um total de 75 pacientes receptores de transplante renal foram incluídos em nossa investigação. O estudo abrangeu um período de observação mediano de 18 (2,0–71,0) meses. A taxa média de filtração glomerular estimada no início foi de 61,9 (26–120) mL/min/1,73 m2 e permaneceu estável durante o acompanhamento. A mediana da HbA1c diminuiu de 7,5 para 7,0% (IC 95%; p<0,002). A melhora significativa no IMC (IC 95%; p<0,001) e no perfil lipídico (IC 95%; p<0,05) também foram observados. A taxa média de hemoglobina no início foi de 13,5g/dL e melhorou modestamente no final do acompanhamento para 13,7g/dL (p=0,12). Em relação à relação proteína/creatinina urinária, os níveis aumentaram ligeiramente, mas não significativamente [+0,05 g/g (p=0,9)]. Numa análise de subgrupo post-hoc, a taxa de infecções do trato urinário foi baixa (10%). Nenhum outro efeito colateral foi observado durante o curso do tratamento. Conclusões: Este estudo demonstra que a administração de inibidores de SGLT2 é viável e bem tolerada, sem efeitos colaterais notáveis em receptores de transplante renal. No entanto, a questão de saber se a inibição do SGLT2 pode efetivamente reduzir a mortalidade cardiovascular e melhorar a sobrevida do enxerto nesses pacientes permanece a ser explorada em estudos subsequentes. Introdução póstransplante pós transplantes SGLT renoprotetores entanto adversos Métodos KTRs. KTRs . (KTRs) A1c Ac c IMC, , (IMC) proteínacreatinina proteína creatinina urinária Resultados 7 investigação 1 2,0–71,0 20710 2 0 71 (2,0–71,0 meses 619 61 9 61, 26–120 26120 26 120 (26–120 mLmin173 mLmin mL min 73 mL/min/1,7 m HbAc HbA 5 7, 70 7,0 IC 95% 95 p<0,002. p0002 p p<0,002 002 p<0,002) p<0,001 p0001 001 p<0,05 p005 05 observados 135gdL gdL 13 5g dL g 137gdL 7g p=0,12. p012 p=0,12 12 (p=0,12) ligeiramente +0,05 005 [+0,0 gg p=0,9. p09 p=0,9 (p=0,9)] posthoc, posthoc post hoc, hoc post-hoc 10%. 10 10% (10%) tratamento Conclusões tolerada subsequentes (KTRs (IMC 2,0–71, 2071 (2,0–71, 6 26–12 2612 (26–12 mLmin17 mL/min/1, p000 p<0,00 00 p<0,0 p00 p01 p=0,1 (p=0,12 +0,0 [+0, p0 p=0, (p=0,9) (10% 2,0–71 207 (2,0–71 26–1 261 (26–1 mLmin1 mL/min/1 p<0, (p=0,1 +0, [+0 p=0 (p=0,9 (10 2,0–7 20 (2,0–7 26– (26– mL/min/ p<0 (p=0, +0 [+ p= (1 2,0– (2,0– (26 mL/min p< (p=0 + [ ( 2,0 (2,0 (2 (p= 2, (2, (p

ABSTRACT Older to older living kidney transplantation is an acceptable alternative to avoid dialysis, improve quality of life and maintain favorable long-term outcomes of patients with end-stage kidney disease. However, the management of these patients is complex and the acceptance of older donors and recipients to kidney transplantation remains controversial. The older recipients usually have several comorbidities that may complicate the postoperative course and increase the risk of end-stage kidney disease. We present a clinical case of living kidney transplantation between an older donor and recipient, both over 70 years old, who evolved to a stage 3 chronic kidney disease, without proteinuria, hypertension, or other complications, three years after transplantation. Our case reinforces favorable outcomes in older living transplantation, both for recipient and donor, as has been demonstrated in several published studies.

ABSTRACT Operational tolerance in kidney transplantation is characterized by stable serum creatinine < 1.7 mg/dL and proteinuria < 1 g/day in the absence of immunosuppression or immunodeficiency for over one year. However, simultaneous donor specific antibodies are common and serum creatinine is a poor surrogate of early lesions. Consequently, subclinical rejections will meet operational tolerance criteria if sérum creatinine remains stable. We report a patient with operational tolerance criteria followed by biopsy-proven chronic active antibody mediated rejection, discussing the intricate challenges of immunosuppression management.

ABSTRACT Peritonitis is a serious complication in peritoneal dialysis, usually secondary to an infectious cause. Chemical peritonitis is rarer. No case exclusively attributed to vancomycin has been reported in the last 20 years. Data from 4 consecutive patients diagnosed with culture‑negative peritonitis following administration of intraperitoneal vancomycin between May and June 2019 were retrospectively recorded. All patients were treated with 2 grams of intraperitoneal vancomycin after a break in aseptic technique and developed a cloudy effluent. No patient was previously known to be allergic to vancomycin. All had a clear dialysate before vancomycin. All developed an elevated leukocyte count in the dialysate. All had sterile cultures. All resumed a clear effluent with less <100 cells/μL after vancomycin cessation, and in two there were no further administrations. In one, a new drug challenge led to recrudescence of abdominal pain and reappearance of a cloudy sterile effluent. In another, vancomycin from a different lot was administrated 3 days after, no symptoms developed and dialysate cell count remained normal. The pathogenic mechanisms underlying chemical peritonitis are not fully known. The clinical course is typically benign. Management seems to be limited to drug withdrawal. If unrecognized, chemical peritonitis may ultimately lead to unnecessary catheter removal.

ABSTRACT Arteriovenous fistulas (AVFs) are the first-choice vascular access for most HD patients. Up to 60% of AVFs do not mature adequately, mostly due to stenosis. Surgical and endovascular techniques can rescue up to 80% of these AVFs from primary failure, allowing them to be safely and effectively used in HD, preserving venous capital, and avoiding placement of CVCs and associated complications. This article reviews and summarizes the existing literature, offering a practical approach on early identification, treatment, and monitoring of immature AVFs.

ABSTRACT Nephrotic syndrome in systemic lupus erythematosus patients with histological evidence of minimal change disease, mesangial proliferation or focal and segmental glomerulosclerosis on light microscopy, represents a distinct clinical entity - lupus podocytopathy. This entity is characterized by a diffuse foot process effacement on electron microscopy and by absence of subepithelial or subendothelial immune‑complex deposition. We report the case of a 49‑year‑old woman admitted on suspicion of lupus nephritis flare, characterized by nephrotic syndrome and acute kidney injury, whose renal biopsy revealed histological features of lupus podocytopathy. Six months after discharge, under prednisolone and azathioprine, she presented 300 mg/day proteinuria, normal kidney function, without hematuria. A review of the pathogenesis, clinical features, diagnostic criteria, treatment and prognosis of lupus podocytopathy is provided. This case highlights the mounting evidence that lupus podocytopathy encompasses distinct clinical and morphological features, that should be included in the upcoming pathological classification of lupus nephritis.

Este artigo analisa a eficiência dos gastos públicos nos municípios fluminenses no período 1999/2000, por meio da aplicação da análise envoltória de dados. O estudo adota os indicadores sociais e de gastos municipais das seguintes áreas temáticas da realidade social: educação e cultura; saúde e saneamento. O artigo apresenta uma revisão de várias aplicações de DEA no campo das políticas públicas e, em seguida, os indicadores e modelos propostos para análise da eficiência dos gastos sociais. Aplicou-se o modelo BCC da DEA, com orientação output, isto é, visando maximizar os outputs sem diminuir os inputs. Foram selecionados indicadores de despesas per capita com educação e cultura e com saúde e saneamento como inputs do modelo em questão. Já as variáveis "candidatas" a outputs foram definidas como: taxa de alfabetização de 10 a 14 anos; proporção de domicílios particulares permanentes com esgotamento sanitário adequado; proporção de domicílios particulares permanentes com saneamento adequado; o inverso da taxa de mortalidade por causas hídricas; a proporção de crianças de dois a cinco anos matriculadas em creches ou escolas de educação infantil. O artigo destaca como "boas práticas", no que se refere à eficiência das políticas públicas, pelos resultados que alcançam em termos do que alocam como recursos ou pelas condições de renda média, os municípios de São Gonçalo, Japeri, Queimados, Cantagalo, São João de Meriti e Resende.

This article analyzes the efficiency of the public spending in cities and towns of the state of Rio de Janeiro during 1999-2000 applying data envelopment analysis. The study adopted social indicators of municipal expenses in following thematic areas of the social reality: education and culture; health and sanitation. The article reviews several DEA applications to public policies and then presents the indicators and models considered for social expenditure efficiency analysis. It adopted the BCC output model of DEA, so as to maximize outputs without decreasing inputs. Indicators of per capita expenditure on education and culture and on health and sanitation were used as inputs of the model in question. The ‘candidates’ for outputs were the following well-being indicators: literacy rate of 10-14 year-old children; ratio of permanent private homes with adequate sanitary disposal; ratio of permanent private homes with proper sanitation; the inverse of mortality rate by sanitation causes; ratio of 2-5 year-old children registered at day child-care centers or children schools. The analysis indicated as ‘good practices’, considering the efficiency of their public expenditure, the cities of São Gonçalo, Japeri, Queimados, Cantagalo, São João de Meriti, and Resende, due to the results they achieve in terms either of resource allocation or of medium revenue.